HIGHLIGHTS
- who: April and collaborators from the Shanghai Jiao Tong, China have published the article: In-silico studies to recognize repurposing therapeutics toward arginase-I inhibitors as a potential onco-immunomodulators, in the Journal: (JOURNAL)
- what: The QSAR VS. predicts the arginase I inhibitory activity (pIC50) of all 1615 FDA compounds, of which 112 have a pIC50 in the range of 8.07-10.023 M. Therefore, a molecular docking study was conducted to determine the binding pattern of these 112 FDA molecules. The authors assess the excretion property of nystatin to estimate the drug`s . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.